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CancerTwo families of E3 ubiquitin ligases are prominent in cell cycle regulation and mediate the timely and precise
ubiquitin–proteasome-dependent degradation of key cell cycle proteins: the SCF (Skp1/Cul1/F-box protein) com-
plex and the APC/C (anaphase promoting complex or cyclosome). While certain SCF ligases drive cell cycle pro-
gression throughout the cell cycle, APC/C (in complex with either of two substrate recruiting proteins: Cdc20
and Cdh1) orchestrates exit from mitosis (APC/CCdc20) and establishes a stable G1 phase (APC/CCdh1). Upon
DNA damage or perturbation of the normal cell cycle, both ligases are involved in checkpoint activation. Mecha-
nistic insight into these processes has signiﬁcantly improved over the last ten years, largely due to a better under-
standing of APC/C and the functional characterization of multiple F-box proteins, the variable substrate recruiting
components of SCF ligases. Here,we review the role of SCF- andAPC/C-mediated ubiquitylation in the normal and
perturbed cell cycle and discuss potential clinical implications of SCF and APC/C functions. This article is part of a
Special Issue entitled: Ubiquitin–Proteasome System. Guest Editors: Thomas Sommer and Dieter H. Wolf.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Themammalian cell cycle is a strictly regulated process controlled by
the oscillating activities of cyclin-dependent kinases (CDKs), which are
activated by cyclins and inhibited by CDK inhibitors (CKIs). Many cyclins
and CDKs have been described, with each cyclin associating with one or
more CDKs, andmost CDKs interacting with one ormore cyclins [1]. The
prototypical cyclins driving cell cycle progression are cyclins A, B, and E,
which are expressed in a cell cycle dependent manner and associate
with Cdk1 or Cdk2 tomediate downstream events, such as DNA replica-
tion and mitosis. Speciﬁcally, cyclin E-Cdk2 is activated in late G1 phase
to promote S-phase entry and DNA replication, cyclin A-Cdk2 and cyclin
A-Cdk1 are involved in S-phase progression and the G2/M transition
respectively, while cyclin B-Cdk1 is activated to promote mitotic entry.
This oscillating activity of CDKs is regulated by diverse mechanisms,
starting from the transcriptional and translational levels, to posttransla-
tional modiﬁcations (phosphorylation in particular), and the periodictin–Proteasome System. Guest
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[2,3]. Contrary to reversible modiﬁcations, such as phosphorylation or
association with CKIs, ubiquitin-mediated proteasomal degradation is
an irreversible mechanism that assures the strict unidirectionality of
the cell cycle, and it plays a key role in cell cycle regulation bymediating
the precise spatial and temporal proteolysis of the main components of
the cell cycle machinery.
Ubiquitylation, the covalent attachment of the small 76-amino-acid
polypeptide ubiquitin to a target protein, occurs through a three-step en-
zymatic cascade. Ubiquitin isﬁrst bound and activated by the E1 ubiquitin
activating enzyme in an ATP dependentmanner. It is subsequently trans-
ferred to the E2 ubiquitin conjugating enzyme, before the E3 ubiquitin li-
gase enzyme speciﬁcally binds the substrate protein to mediate the
transfer of ubiquitin to a lysine residue in the target [4]. Several rounds
of ubiquitin conjugation produce long ubiquitin chains in which each
ubiquitinmolecule is covalently bound to a speciﬁc lysine of the previous
ubiquitin moiety (polyubiquitylation). In the case of polyubiquitylation
via lysine 48 or lysine 11, the polyubiquitylated substrate is committed
to association with, and subsequent degradation by, the 26S proteasome.
However, there are different types of ubiquitylation, which can lead to
other molecular consequences, depending on the nature of the E2.
Indeed, substrates can be monoubiquitylated or polyubiquitylated
through ﬁve other internal lysine residues (K6, K27, K29, K33, and
K63) or the N-terminus of ubiqutin [5–7]. While monoubiquitylation
or K63-linked polyubiquitylation speciﬁes non-proteolytic fates for a
substrate, the implications of other chain linkages are less understood
[5,7,8]. Ubiquitylation itself can be reversed by speciﬁc deubiquitinating
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trolled by the balance between an E3 ligase and a DUB [9].
To allow for high speciﬁcity in the ubiquitylation of target pro-
teins, more than 600 different E3 ligases exist in the human genome
[10]. Depending on their homology domains, these ligases can be
subdivided in two major classes, the HECT (homologous to E6-AP
C-terminus) family E3 ligases and the RING (really interesting new
gene) family E3 ligases [11]. The approximately 30 different HECT li-
gases form transient covalent linkages with ubiquitin during the
ubiquitylation process, while RING ligases only mediate the transfer
of ubiquitin from the E2 directly to the substrate. RING E3 ligases
can be further subcategorized into those in which one protein con-
tains both the RING and the substrate adaptor domain or multi-
subunit complexes, in which these domains are part of distinct pro-
teins within the complex [11]. One of the best described E3 families
within the multi-subunit RING ligases is the cullin RING ligase
(CRL) superfamily [12], which includes the CRL1 (better known as
SCF, standing for Skp1–Cul1–F-box protein complex) and the APC/C
(anaphase promoting complex/cyclosome, which is also referred to
as a CRL-like ligase) E3 ligases.
The SCF complex consists of Cul1, the scaffold of the complex, Rbx1,
the RING protein, which eventually recruits the E2, and Skp1 (S-phase
kinase associated protein 1), which serves as an adaptor to bind the
F-box protein, the substrate-binding subunit (Fig. 1) [12–14]. F-box
proteins are named after the F-box domain, a 40-amino-acid motif ini-
tially identiﬁed in cyclin F (aka Fbxo1), which binds Skp1 [15]. They
contain an additionalmotif, which constitutes the substrate binding do-
main. Depending on these domains, they are classiﬁed into three
groups. F-box proteins containing WD-40 domains are called Fbxws,
while those with leucine-rich repeats are called Fbxls. The remaining
F-box proteins, with other motifs (e.g., tetratrico peptide repeats,
kelch repeats, proline-rich motifs) are named Fbxos [13,16,17].
Sixty-nine different F-box proteins are encoded by the human
genome, and individual F-box proteins recognize different substrates.
Therefore, these proteins determine the broad functional bandwidth
of SCF complexes. Importantly, speciﬁc substrates or biological activ-
ities have so far been assigned to only a few F-box proteins, and each
of these plays a key role in essential cellular processes, such as cell
cycle control, apoptosis, DNA damage responses, gene transcription,
or translation [3,18].
The APC/C is a prominent E3 ubiquitin ligase involved in cell cycle
regulation. It consists of thirteen different subunits and, in somaticApc2
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Fig. 1. Structure of the SCF and the APC/C ubiquitin ligases. The SCF and APC/C E3 li-
gases are both members of the Cullin-RING ligase (CRL) superfamily. Cul1 and Apc2
(light grey) are the scaffold proteins of SCF and APC/C, respectively. On one end, they
bind to a RING ﬁnger protein, Rbx1 or Apc11 (dark grey), which recruits the E2
ubiquitin conjugating enzyme (UBC). On their other end, they connect to the substrate
speciﬁc unit via an adaptor molecule (red). In the case of SCF, the F-box proteins are
the variable substrate binding components (orange), while Cdh1 and Cdc20 (in somatic
cells), together with Apc10, recruit substrates to the APC/C. The scheme illustrates the
relationship between APC/C and SCF components and does not represent the topology
of APC/C subunits.cells, has two co-activators: Cdc20 and Cdh1 (also known as Fzr1),
which deﬁne substrate speciﬁcity and associate with the APC/C core
at deﬁned stages of the cell cycle (Fig. 1) [19]. While SCF ligases can
be active throughout the cell cycle, APC/C activity is restricted to the
time between metaphase and the end of the next G1, and during
this time, APC/CCdc20 initiates anaphase and mitotic exit, while APC/
CCdh1 contributes to mitotic exit and establishment of a stable G1
state [3,20–22].
In the following sections, we outline the current understanding of
how SCF and APC/C E3 ligases regulate cell cycle progression, their re-
sponse to environmental cues in each phase of the cell cycle, and po-
tential clinical and therapeutic implications of SCF and APC/C biology.
2. The G0 and G1 phases
2.1. Quiescence and G1
In response tomitogenwithdrawal (or after exit frommitosis), a sta-
ble G0 or G1 state has to be established. The APC/CCdh1 complex is the
central player in this task, and it is activated in late mitosis to complete
mitotic exit and reset the cell cycle by targeting a variety of proteins in-
volved in DNA replication, cycle progression, and mitosis. Among the
targets that promote DNA replication is Cdc6, which binds to the origin
recognition complex (ORC) to form pre-replication complexes (preRCs).
Cdc6 is kept at low levels during early G1 through APC/CCdh1-mediated
degradation (Fig. 2A) [23]. APC/CCdh1 also negatively regulates pro-
proliferative signal transduction by targeting Ets2 (Fig. 2A), a transcrip-
tion factor involved in Ras–Raf–MAPK signaling that induces the expres-
sion of cyclin D1 [24,25]. APC/CCdh1 activity also precludes early
accumulation of positive cell cycle regulators [21,26]. Speciﬁcally, Skp2
(Sphase kinase-associated protein 2, aka Fbl1) is targeted for proteolysis
to avert premature formation of the SCFSkp2 complex, which promotes
cell cycle progression by mediating the degradation of CKIs (see below
and Fig. 2A) [26–28]. Importantly, the Cdc25A phosphatase, which pro-
motes S-phase entry andmitosis by dephosphorylating and thus activat-
ing Cdk2 and Cdk1, is also kept at low levels during early G1 by APC/
CCdh1 (Fig. 2A) [29]. Finally, APC/CCdh1 targets mitotic proteins for
proteasomal degradation [19–21,30]. Among the most prominent tar-
gets are cyclin A and cyclin B (Fig. 2A), the main drivers of mitotic
entry [31,32]. Furthermore, Aurora A, Aurora B, and polo-like kinase 1
(Plk1), important mitotic kinases involved in centrosome maturation,
spindle assembly, and chromosome separation, are additional targets
of APC/CCdh1 (Fig. 2A) [33–36].
Hence, by targeting protooncogenic proteins, such as Skp2 and Ets2,
APC/CCdh1 exerts an anti-proliferative activity. In fact, APC/CCdh1 acts as
a tumor suppressor inmice, where Fzr1 heterozygousmice have elevat-
ed rates of spontaneous tumor formation [37].
In response to mitogen withdrawal, cells must also switch to a state
of nutritional saving and restrict protein translation and cell growth to
sustain survival. SCFFbxo9 contributes to this process via differential
regulation of mTORC1 and mTORC2 signaling. Speciﬁcally, the Tel2
(telomere maintenance 2) and Tti1 (Tel2 interacting protein 1) pro-
teins, integral components of both the mTORC1 and mTORC2 com-
plexes, are phosphorylated by CKII to target them for degradation by
SCFFbxo9 upon growth factor withdrawal. This pathway speciﬁcally tar-
gets Tel2 and Tti1 in the mTORC1 complex (Fig. 2B) [38]. As a conse-
quence, mTORC1 signaling is attenuated to restrain protein translation
and cell growth, but via relief of mTORC1-mediated feedback inhibition,
mTORC2 signaling is sustained to promote survival [38].
2.2. The growth factor response
If growth factors and nutrients are available, cells respond with a
number of events that lead to growth and, eventually, cell division.
Certain SCF ligases are acutely involved in the orchestration of growth
factor responses during G1 phase. For example, the tumor suppressor
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Fig. 2. SCF and APC/C mediated degradation processes in G1 phase and the response to mitogen stimulation. A. APC/CCdh1 maintains a stable G1 phase by targeting mitotic proteins
like Aurora A, Aurora B, Plk1, cyclin A, and cyclin B for degradation. In addition, APC/CCdh1 prevents premature accumulation of positive cell cycle regulators, such as Ets2, Cdc6, and
Cdc25A. The CDK inhibitors p21 and p27 are stabilized via APC/CCdh1-dependent degradation of Skp2 to keep CDK activity low during G1. B. Upon mitogen stimulation, SCFβTrCP
mediates the degradation of inhibitory or proapoptotic proteins, such as PCDC4, DEPTOR, and BimEL, promoting cell growth. Upon mitogen withdrawal, SCFFbxo9 targets Tel2
and Tti1 for degradation within mTORC1 to attenuate mTORC1 activity and sustain mTORC2 signaling. C. At the G1/S transition, APC/CCdh1 activity is inhibited through several mech-
anisms, such as inhibitory phosphorylation by CDKs and binding to Emi1. Skp2-dependent degradation of p21 and p27 leads to activation of cyclin E-Cdk2, which initiates S phase
before being degraded via SCFFbw7. See main text for more details.
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tion initiation factor eIF4A, is degraded in response to mitogens in a
two-step mechanism. First, PDCD4 is phosphorylated on serine 67
(and possibly adjacent serine residues) by S6K1, and it is subsequently
ubiquitylated via SCFβTrCP (Fig. 2B), resulting in increased protein syn-
thesis and cell growth [39]. In response tomitogens and survival signals,
SCFβTrCP furthermore promotes survival by targeting the proapoptotic
BH3-only protein BimEL for degradation in an Rsk1/2- and Erk1/2-
dependent manner (Fig. 2B) [40]. Another important target of SCFβTrCP
in growth factor responses is the mTOR inhibitor DEPTOR (Fig. 2B).
After mitogen stimulation, DEPTOR is phosphorylated by mTORC1 or
mTORC2 and CK1α, which directs ubiquitylation and degradation, re-
lieving mTOR inhibition [41,42]. Thus, in cooperation with SCFβTrCP,
mTOR signaling promotes further mTOR activation via this auto-
ampliﬁcation loop.
2.3. Post-restriction point G1 and the G1 to S phase transition
With sufﬁcientmitogen stimulation and cell growth, cells commit to
cell division, passing a point of G1 known as “restriction point”, after
which cells will proceed through a round of cell division even if mito-
gens are removed. The transition from G1 to S phase results from
decreasing APC/CCdh1 activity, decreasing CKIs levels, rising cyclin ex-
pression, increasing CDK activity, phosphorylation and inactivation of
Rb (retinoblastoma) protein family members, and activation of E2F
transcription factor family members.
Inactivation of APC/CCdh1 during progression through the late G1
phase occurs via different mechanisms. First, UbcH10, the APC/C spe-
ciﬁc E2 ubiquitin conjugating enzyme, is ubiquitylated by APC/CCdh1(Fig. 2C), thereby providing a negative feedback loop limiting APC/
CCdh1 activity [43]. Likewise, Cdh1 initiates autoubiquitylation within
APC/C (Fig. 2C), thus limiting its activity [44]. Furthermore, rising
levels of CDK activity lead to phosphorylation of Cdh1, disrupting its
binding to APC/C (Fig. 2C) [3,45]. Later, in S-Phase, an unidentiﬁed
SCF complex contributes to Cdh1 degradation (Fig. 2C), either directly
or indirectly, and this process may depend on previous Cdh1-
phosphorylation [46]. Finally, at the G1/S transition, the transcription
factor E2F induces expression of Emi1 (an F-box protein also known
as Fbxo5), which binds to APC/CCdh1 as a pseudosubstrate inhibitor,
inhibiting APC/CCdh1 throughout S and G2 (Fig. 2C) [47,48].
Rising CDK activity during G1 phase occurs through several different
mechanisms. Primarily, the expression of cyclins is induced on a tran-
scriptional level, with cyclin E and cyclin A expression being initiated
by E2F (Fig. 2C) [49,50]. However, themajority of cyclin-Cdk complexes
are inhibited via association with CDK inhibitors (CKIs), such as p21 or
p27. In late G1, Cdk4 and Cdk6 bound to cyclin D1 catalyze the phos-
phorylation (and consequent inactivation) of Rb family proteins (pRb,
p107, and p130), which bind and inhibit E2F transcription factors,
preventing their promotion of cell cycle progression. With decreasing
APC/CCdh1 activity in late G1, Skp2 accumulates and forms the SCFSkp2
complex (Fig. 2C), which targets cell cycle inhibitors for degradation,
promoting cell cycle progression throughout S, G2, and M [22]. Impor-
tantly, SCFSkp2 binds p27 and mediates its proteasomal degradation,
liberating cyclin E-Cdk2 from p27 inhibition (Fig. 2C) [51–54].
Ubiquitylation of p27 depends on phosphorylation of threonine 187
by cyclin E-Cdk2 and the co-factor Cks1 [55–59]. Other CKIs
ubiquitylated by SCFSkp2 include p21 and p57, whose degradation fur-
ther reinforces cyclin-Cdk1/2 activation [60,61]. By analogy to p27,
153F. Bassermann et al. / Biochimica et Biophysica Acta 1843 (2014) 150–162phosphorylation by cyclinE-Cdk2 and binding of Cks1 are likely prereq-
uisites for SCFSkp2 dependent ubiquitiylation of p21 and p57 [60,61].
These functions distinguish Skp2 as an E3 ligasewith oncogenic proper-
ties, which is further supported by the frequent overexpression of Skp2
in many tumors [62].3. S and G2 phases of the cell cycle
3.1. S phase
Cyclin E-Cdk2 and (later) cyclin A-Cdk2 are the two main CDK
complexes in S phase andmediate the initiation of DNA and centrosome
duplication. At the same time, cyclin A-Cdk2 further inhibits APC/CCdh1
via Cdh1 phosphorylation to ensure cyclin stability (Fig. 3A) [43]. Upon
successful S-phase entry, cyclin D1 is phosphorylated by GSK3β,
targeting it for degradation by an SCF ligase containing Fbxo4 and the
small heat-shock protein α/B-crystallin (the latter being a substrate
adaptor) [63]. As cells progress through S and approach G2, the levels
of S phase cyclins decrease again. Notably, cyclin E abundance is regu-
lated via a negative feedback loop. Speciﬁcally, as Cdk2-activity in-
creases, Cdk2-bound cyclin E is phosphorylated on threonine 380 in
a Cdk2-dependent manner, whereupon phosphorylated cyclin E is
targeted for degradation by the SCFFbw7 complex (Figs. 2C and 3A)
[64,65].B
SCF
Skp2
Cyclin A
Cdk 1/ 2
p21
p27
SCF
Fbw7
CDKs
Cyclin E
APC
Cdh1
Emi1
X
early G2A
SCF
TrCP
Wee1
Cyclin B
Cdk 1
Pl
k1
Aur A
Plk1
Bora
SCF
NIPA
X
X
Erk
mitotic entry
G2/M transition
Fig. 3. SCF and APC/C mediated degradation processes in S and G2 phases of the cell cycle. A
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CP110) are also degraded via cyclin F to stop dNTP production and assure centrosomes are o
p21 and p27, while Wee1 is degraded in a Plk1- and SCFβTrCP-dependent manner to release3.2. DNA damage checkpoint
During S and G2 phases, it is crucial for cells to assure accurate and
complete DNA replication. Therefore, DNA damage detection mecha-
nisms and checkpoints provide precise surveillance. UponDNAdamage,
ATM activates the checkpoint kinase Chk2 and ATR activates Chk1 in a
Claspin-dependent process (Fig. 4). Chk1 and Chk2 thenmediate inhib-
itory phosphorylation of Cdc25A on serine 216 [66,67]. Cdc25A pro-
motes cell cycle activation by virtue of its ability to remove inhibitory
phosphorylations from Cdk1 and Cdk2, but Cdc25A phosphorylation
by Chk1/2 results in ubiquitylation by SCFβTrCP and degradation, atten-
uating CDK activity (Fig. 4) [68]. Degradation of Cdc25A leads to a
pause in cell cycle progression during S or G2, depending on the timing
of the DNA damage.
Another target of the DNA damage checkpoint in G2 phase is Plk1
[69,70]. In response to DNA damage, the phosphatase Cdc14B is re-
leased from the nucleolus to the nucleoplasm, where it dephosphory-
lates Cdh1 (Fig. 4). As a consequence, APC/CCdh1 becomes reactivated
to target Plk1 for degradation (Fig. 4). In this way, Claspin and Wee1
are stabilized to activate the checkpoint and inhibit cell cycle progres-
sion (Fig. 4) [70]. Notably, other known targets of APC/CCdh1 are likely
protected during this process by DUBs, particularly USP28 [70,71].
SCFβTrCP also plays a role during recovery from the checkpoint.
Claspin, which mediates ATR-induced activation of Chk1 upon DNA
damage, is phosphorylated by Plk1 during checkpoint recovery andSCF
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Fig. 4. Role of SCF and APC/C ligases in the response to DNA damage. Upon DNA damage, SCF and APC/C activate S and G2 checkpoints to halt cell cycle progression. Chk1 (which is
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consequence, activation of Chk1 declines, and the cell recovers from
the checkpoint. Moreover, SCFβTrCP also regulates translation during
the silencing of the G2 DNA damage checkpoint. In response to
genotoxic stress, AMPK (adenosine monophosphate-activated protein
kinase) phosphorylates and activates eEF2K (eukaryotic Elongation Fac-
tor 2 Kinase),which, in turn, inhibits elongation byphosphorylating and
inhibiting eEF2, a protein that mediates movement of the ribosome
along mRNA [74]. During checkpoint silencing, SCFβTrCP targets eEF2K
for degradation to enable rapid resumption of translation elongation
[74].
3.3. G2 phase and G2/M transition
After successful and accurate completion of DNA replication, pro-
duction of deoxyribonucleotides (dNTPs) must be avoided. To this
end, RRM2 (ribonucleotide reductase family member 2), which con-
verts ribonucleotides to dNTPs for DNA synthesis, is phosphorylated
on threonine 33 by CDKs and ubiquitylated by the SCFCyclinF complex,
reducing the availability of dNTPs (Fig. 3A) [75]. In contrast, cyclin F is
downregulated in response to DNA damage in an ATR-dependent
manner to stabilize RRM2 (Fig. 4). By this means, production of
dNTPs is enhanced to allow for efﬁcient DNA repair [75].
Beyond DNA replication, SCFCyclinF also regulates centrosome du-
plication. Cyclin F and CP110, a protein essential for centrosome du-
plication, physically associate on the centrioles during G2 [76]. By
targeting CP110 for proteasomal degradation (Fig. 3A), SCFCyclinF as-
sures that centrosomes are replicated only once during the cell
cycle, preventing centrosome overduplication, which could lead to
multipolar or asymmetric mitotic spindles and subsequent chromo-
some aberrations [76].
With progression through G2 phase, the cell prepares for mitotic
entry, which is orchestrated by cyclin B-Cdk1. Therefore, cyclin
B-Cdk1 is a strictly regulated kinase complex. In late G2 phase,
SCFβ-TrCP promotes activation of Cdk1 by mediating the degradation
of Wee1, a Cdk1 inhibitory kinase (Fig. 3B). A prerequisite for
SCFβ-TrCP binding to Wee1 is phosphorylation of serine 53 and serine
123 by Plk1 and Cdk1, respectively [77]. Thus, a positive feedback
loop between Cdk1 activation and Wee1 degradation assures rapid
activation of Cdk1 upon mitotic entry (Fig. 3B). The activity of Plk1itself is also tightly controlled through the synergistic actions of
Bora and Aurora A kinase. Accumulation of Bora during G2 leads to
Aurora A-mediated activation of Plk1, which contributes to Wee1
degradation and subsequent activation of Cdk1 (Fig. 3B) [78].
To preclude premature mitotic entry, early activation of cyclin
B-Cdk1 must be prevented. To this end, SCFNIPA targets nuclear cyclin
B1 during S andG2 (Fig. 3A) [79]. However, in late G2, NIPA is phosphor-
ylated at serine 395 by cyclin B-Cdk1, after initial phosphorylation on
serine 354 and serine 359 by Erk2 (Fig. 3B) [80,81]. Phosphorylation
inhibits assembly of a functional SCFNIPA complex, allowing nuclear
accumulation of cyclin B1 and subsequentmitotic entry. In this context,
cyclin B1 regulates its own abundance through a positive feedback loop
(Fig. 3B).
4. Mitosis
4.1. Prometaphase and spindle assembly checkpoint
Cyclin B-Cdk1 orchestrates essential steps of early mitosis, including
the assembly of themitotic spindle, breakdown of the nuclear envelope,
cessation of gene transcription, and condensation of chromosomes.
These processes drive the cell through prophase until metaphase.
Starting from metaphase, the APC/C becomes a key player in pro-
motingmitotic progression and, eventually, mitotic exit. Thus, inhibito-
ry mechanisms that keep the APC/C in check throughout S- and G2
phasesmust be removed. In this regard, SCFβTrCPmediates ubiquitylation
and degradation of the APC/C inhibitor Emi1 following phosphorylation
by cyclin B-Cdk1 and Plk1 in early mitosis (Fig. 5A) [82,83]. However,
until all kinetochores are correctly attached to spindle ﬁbers and the
chromosomes are properly aligned on the metaphase plate, the Spindle
Assembly Checkpoint (SAC) inhibits APC/C activation, blocking the
onset of anaphase [84]. In the presence of unattached kinetochores,
the mitotic checkpoint proteins, BubR1, Bub3, and Mad2, bind to Cdc20
to form the Mitotic Checkpoint Complex (MCC), which sequesters
Cdc20 and directly inhibits activation of the APC/CCdc20 (Fig. 5A)
[84–86]. Another model suggests that Cdc20 is targeted for degradation
by APC/C in an MCC-dependent manner during SAC activation [87,88].
Furthermore, inhibitory phosphorylation of Cdc20 by protein kinases,
such as Cdk1 (Fig. 5A), MAPK, or Bub1, contributes to Cdc20 inhibition
during SAC activation [89–91]. Interestingly, the transcription of Mad2
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(Repressor-Element-1-Silencing Transcription factor) for degradation,
allowing transcriptional derepression of Mad2 (Fig. 5A) [92].
Despite themanymechanismskeepingAPC/CCdc20 in check, its activ-
ity is not completely inhibited; a minor fraction remains active even
during SAC activation. This subpopulation sustains cyclin B-Cdk1 activity
during prometaphase by targeting p21 for degradation (Fig. 5A) [93].
Although p21 is degraded via SCFSkp2 at the G1/S transition, it re-
accumulates during G2 and interacts with cyclin B-Cdk1 before it is
ubiquitylated by APC/CCdc20. Interestingly, APC/CCdc20 and APC/CCdh1
have opposing effects on p21 levels. While p21 is degraded via APC/
CCdc20 in early mitosis, APC/CCdh1 indirectly stabilizes p21 in G1 phase
by targeting Skp2 and Cdc20 for degradation [27,94,95]. In addition,
APC/CCdc20 targets two other substrates for degradation in early mitosis,
cyclin A and Nek2A, even when the spindle checkpoint is active. How
the checkpoint-resistant activity of the APC/CCdc20 is regulated remains
unclear. Potential mechanisms include Cdc20-independent binding of
substrates to APC10 or an increase in substrate afﬁnity for Cdc20,
which allows substrates to outcompete SAC proteins [96–98].
4.2. Metaphase to anaphase transition and mitotic exit
Upon proper attachment of all spindle microtubules to chromo-
some kinetochores, the SAC is rapidly inactivated, and APC/CCdc20 is
released from inhibition via an uncertain mechanism (Fig. 5B).Checkpoint inactivation depends on Cdc20-dependent ubiquitylation.
According to some, this leads to dissociation of the MCC from APC/
CCdc20, but others suggest that it causes degradation of Cdc20
[99,100]. An additional, ATP-dependent step is also required for
both dissociation of the MCC from APC/C and disassembly of the
free MCC [101,102]. This step has been shown to involve β–γ bond
cleavage of ATP, suggesting the presence of an additional ubiquitin in-
dependent process, whichmay be kinase- or chaperone-related [102].
The understanding of SAC inactivation is further complicated by
the fact that Cdc20 proteolysis is also stimulated by Mad2 and
BubR1 to keep levels of Cdc20 low in order to avoid premature activa-
tion of APC/C and maintain the checkpoint [87,88]. Eventually, after
kinetochore attachment, activated APC/CCdc20 initiates anaphase by
targeting Securin for degradation (Fig. 5B) [20,103,104]. Duringmeta-
phase, sister chromatids are held together by Cohesin. Securin is a
chaperone that binds and inhibits Separase, an enzyme capable of
cleaving Cohesin. With Securin degradation, Separase is released,
and centromeric Cohesin is cleaved, which leads to sister chromatid
segregation (Fig. 5B) [105]. Moreover, Shugoshin, a protector of cen-
tromeric sister chromatid cohesion, is targeted for degradation by
APC/CCdh1; however, this step is not indispensable for chromatid seg-
regation and seems more important during meiosis [106,107].
Bothmitotic cyclins, cyclin A and cyclin B, are targeted for degradation
by the APC/C (Fig. 5B) [108]. Whereas cyclin A degradation starts in
prometaphase, cyclin B ubiquitylation starts at the metaphase/anaphase
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Notably, APC/CCdc20 has different effects on Cdk1 activity depending on
the mitotic phase. While it augments cyclin B-Cdk1 activity during
prometaphase via degradation of p21 (Fig. 5A), it suppresses cyclin
B-Cdk1 via degradation of cyclin B in late mitosis (Fig. 5B) [93]. Mitotic
cyclin-CDK activity inhibits separase, so the degradation of cyclin A and
cyclin B byAPC/CCdc20 is directly involved in sister chromatid separation
(Fig. 5B) [20]. Furthermore, drastically reduced CDK activity in ana-
phase allows for disassembly of the mitotic spindle, chromosome
decondensation, cytokinesis, and reconstitution of the nuclear envelope
[20].
Although APC/C is the most prominent E3 ubiquitin ligase orches-
trating the metaphase to anaphase transition, SCF ubiquitin ligases are
also involved in the regulation of anaphase onset. For instance, Bora,
which works together with Plk1 and Aurora A to regulate microtubule
polymerization, spindle stability, and tension between kinetochores, is
targeted for degradation by SCFβTrCP at the metaphase to anaphase
transition (Fig. 5A) [112,113]. Interestingly, a prerequisite for Bora
ubiquitylation is phosphorylation by Plk1, which itself is activated in a
Bora-dependentmanner at the G2/M transition [78,112]. Timely activa-
tion and degradation of Bora assure regulated cell cycle progression, as
inhibition of Bora degradation delays anaphase onset and knockdown
of Bora activates the spindle checkpoint [112,113].
In late mitosis, Aurora A and Plk1 are eventually targeted for
degradation via the APC/CCdh1 to promote mitotic exit (Fig. 5B)
[33,34,36]. Another important substrate of APC/C in late mitosis is
Geminin (Fig. 5B), which inhibits DNA re-replication by precluding
formation of the pre-replication complex (pre-RC) after S-phase, ren-
dering replication possible during the subsequent cell cycle [114].
Overall, the APC/C is the central E3 ligase that coordinates mitotic
progression, mitotic exit, and the subsequent establishment of a G1
state. While anaphase onset is induced by APC/CCdc20, both APC/
CCdc20 and APC/CCdh1 orchestrate mitotic exit, and APC/CCdh1 contrib-
utes to establishment and maintenance of the G1 phase of the next
cell cycle. This distinct activation proﬁle is the result of different reg-
ulatory steps. As mentioned earlier, Cdh1 is kept inactivated via phos-
phorylation by CDKs during S, G2 and part of mitosis [115].
Degradation of cyclin B reduces CDK activity at the metaphase to
anaphase transition, so the levels of dephosphorylated Cdh1 rise.
Dephosphorylated Cdh1 binds APC/C and negatively regulates APC/
CCdc20 by targeting Cdc20 for degradation (Fig. 5B) [94,95]. Moreover,
APC/C dependent autoubiquitylation of Cdc20 in anaphase has been
proposed to further contribute to the inactivation of APC/CCdc20
(Fig. 5B) [99,100]. The oscillation between Cdc20 and Cdh1 expres-
sion partly explains how the APC/C times the degradation of its
various substrates. Depending on their destruction box and their
afﬁnity for Cdc20 or Cdh1, APC/C substrates will be targeted earlier
or later during mitosis or G1 for proteasomal degradation [116,117].
5. Other CRLs involved in cell cycle control
Other CRLs are also implicated in cell cycle control and the DNA
damage response. CRL3 complexes appear to control mitosis via pro-
teolytic and non-proteolytic mechanisms. The best understood cell
cycle-related CRL3 substrate is Aurora B. K63-type ubiquitylation of
Aurora B targets it to mitotic chromosomes to control their alignment
[118]. The CRL4 ligases also control features of the cell cycle. In addi-
tion to Cul4 and Rbx1, CRL4 ligases contain the adaptor protein DDB1
(DNA Damage Binding protein 1), which recruits members of the
DCAF (DDB1–Cul4 Associated Factors) family to dictate the speciﬁcity
of substrate degradation [119–121]. CRL4Cdt2 is a prominent member
of this family implicated in DNA replication and the DNA damage re-
sponse. Notably, CRL4Cdt2 interacts with different UBCs (UBCH8,
UBE2G1, and UBE2G2) to mediate ubiquitylation of its various sub-
strates [122]. An important target of CRL4Cdt2 is Cdt1, a replication li-
censing factor and pre-replication complex (pre-RC) component thatis tightly regulated to ensure that DNA replication only occurs once per
cell cycle. After S phase, Cdt1 activity is attenuated both by Geminin bind-
ing and by proteasomal degradation. Importantly, CRL4Cdt2-mediated
degradation of Cdt1 is initiated shortly after S phase onset [123–126].
This event requires Cdt1 binding to PCNA via a PIP (PCNA interacting
protein)-box motif present in Cdt1. Upon DNA damage, Cdt1 is degraded
in the sameway to preclude DNA replication [127]. (Interestingly, Cdt1 is
also targeted for degradation by SCFSkp2 in response to CDK-dependent
phosphorylation [123,128].)
An additional target of CRL4Cdt2 is p21, which is degraded both in
response to UV-induced DNA damage and during the unperturbed
cell cycle. In the later context, CRL4Cdt2 collaborates with SCFSkp2 to
mediate timely degradation of p21. Like Cdt1, p21 degradation by
CRL4Cdt2 requires interaction with PCNA via a PIP-box [129]. CRL4Cdt2
is further involved in cell cycle control via regulation of histone meth-
ylation by ubiquitylation of Set8. Set8 mono-methylates Lys 20 of his-
tone H4 (H4K20me1) during G2 to promote chromatin compaction.
During S phase and upon DNA damage, Set8 is degraded by CRL4Cdt2
in a PCNA-dependent manner [130–132]. Perturbation of this mecha-
nism leads to accumulation of H4K20me1, premature chromatin
compaction, and activation of the G2/M checkpoint [130,131].
Interestingly, Cdt2 levels are regulated via SCFFbxo11 during the
cell cycle [133,134] and inhibition of Cdt2 degradation delays cell
cycle exit. In contrast to most other SCF substrates, whose phosphor-
ylation promotes binding to the F-box protein, CDK-dependent phos-
phorylation of the Cdt2 degron inhibits binding to and degradation
via Fbxo11 [134]. Thus, crosstalk between an SCF ligase, CDKs, and a
CRL4 complex controls the abundance of Cdt2 to regulate the timing
of cell cycle exit.
6. Clinical implications
6.1. SCF complexes as targets in the therapy of cancer and other diseases
The SCF complexes and the APC/C are key players in cell cycle con-
trol and the DNA damage response. As such, they govern cell prolifera-
tion and genome stability, which, when deregulated, contribute to
tumorigenesis. Among the SCF ligases controlling cell growth and pro-
liferation (discussed above), this situation has been described in partic-
ular for SCFSkp2, SCFTrCP, SCFFbxw7, and SCFFbxo9. The recent therapeutic
success of the proteasome inhibitor bortezomib in multiple myeloma
and certain types of B-cell Non-Hodgkin's lymphoma has expedited
the efforts to develop inhibitors of ubiquitin ligases or its components
[135,136]. While bortezomib exhibits a certain degree of selectivity
towards cancer cells and has a noticeable therapeutic index, it
non-speciﬁcally blocks the ubiquitin–proteasome-dependent degrada-
tion of all cellular proteins, resulting in considerable side effects and
the development of resistance. Therapies directed against individual
E3 ligases or ligase families known to be deregulated in human cancers
may thus prove more efﬁcacious. To qualify as a target for therapeutic
inhibition, a ligase should be an oncoprotein (based on the activity of
its substrates — e.g., tumor suppressors) and deregulated in tumors.
6.1.1. Skp2
Skp2 is an oncoprotein by virtue of its function in degrading negative
cell cycle regulators, including p27, p21, p130, and p57 [137,138]. Skp2 is
overexpressed in various malignancies, such as gastric cancer [139,140],
colon cancer [141], and breast cancer [142], with an associated decrease
in p27 levels and indicating a poor prognosis. The oncogenic function of
Skp2 is further underscored by mouse genetic studies. Targeted expres-
sion of Skp2 in the T-lymphoid lineage cooperates with activated N-Ras
to induce T-cell lymphomas [143], while tissue speciﬁc expression of
Skp2 in the prostate induces hyperplasia and low grade carcinoma
[144]. In addition, a critical role for Skp2-dependent degradation of p27
in colon adenoma-carcinoma development was demonstrated using
a Skp2 knock-in model [145]. Similarly, in Skp2-null cells, aberrant
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potent, tumor-suppressive senescence response, although Skp2 inactiva-
tion alone does not induce senescence [146]. Finally, RNAi-mediated
knockdown of Skp2 inhibits the growth of tumor cells, including cell
lines derived from glioblastoma [147], melanoma [148], and oral cancer
[149]. Speciﬁc inhibition of Skp2 would thus be expected to be effective
in the treatment of cancers with activated Skp2 signaling.
Interestingly, Skp2 also interacts with a number of proteins pro-
duced by pathogenic viruses, such as X-protein (HBV), EBNA3C
(EBV), and E7 (HPV16/18) [150], suggesting that Skp2 inhibitors
may be also utilized in certain viral infections.
6.1.2. βTrCP
Given the diversity of its substrates (reviewed in [151]), βTrCP
might be expected to exert both oncogenic and tumor suppressor activ-
ities. However, in certain tissues, βTrCP is clearly an oncoprotein based
on its ubiquitylation activity against tumor suppressors, such as IκB, a
negative regulator of NFκB [152], PDCD4, an inhibitor of eIF4A-
mediated protein translation [39], and BimEL, a potent proapoptotic
protein [40]. Indeed, βTrCP is overexpressed in breast cancer [153],
and forced overexpression of βTrCP induces transformation in breast
epithelium [154]. Likewise, upregulation of βTrCP has been shown in
colon cancer, where it correlates with elevated NFκB activity and
poor prognosis [155] and in pancreatic cancer cells, where it impacts
chemoresistance [156]. Further evidence demonstrating the oncogenic
potential of βTrCP stems from transgenic mouse models, in which
tumor formationwas observed in themammary gland, liver, and kidney
when βTrCP expression was directed to these tissues [154,157]. Inter-
estingly, no obvious phenotypewas observed upon targeted expression
of βTrCP in lymphoid organs, suggesting that βTrCP-dependent tumor-
igenesis is tissue speciﬁc [154]. Therefore, disrupting the interaction of
βTrCP and its tumor suppressive substrates may be an attractive thera-
peutic strategy in deﬁned tumor entities.
Similarly to Skp2, βTrCP interacts with a number of proteins pro-
duced by pathogenic viruses, such as Tax (HTLV1). Moreover, the
HIV-1 protein Vpu targets SCFβTrCP to CD4 [158]. This ﬁnding, together
with the evidence that other HIV-1 proteins (i.e. Vif and Vpr) bind
CRLs to eliminate cellular proteinswith antiviral activity (e.g., APOBEC3),
indicates that SCFβTrCP and other CRLs are involved in the HIV life cycle
and represent potential targets in the ﬁght against this virus.
6.1.3. Fbxo9 and Fbxw7
The rationale for targeting the ubiquitin–proteasome system is
particularly evident in multiple myeloma, due to the high efﬁcacy
of proteasome inhibitors in this disease. Indeed, Bortezomib, a revers-
ible proteasome inhibitor, has been approved as the ﬁrst line treatment
for multiple myeloma. In addition, Carﬁlzomib, a second generation ir-
reversible proteasome inhibitor has recently been approved by the
Food and Drug Administration (FDA) for the treatment of patients
with relapsed and refractory multiple myeloma, and demonstrates in-
creased potency and an improved therapeutic index [159,160]. Two
ubiquitin ligases of the SCF family have recently been reported to
contribute to the pathogenesis of multiple myeloma, SCFFbxo9 and
SCFFbxw7α.
As outlined above, Fbxo9 targets Tel2/Tti1 proteins in a CK2-
dependent manner to adjust mTOR signaling to the availability of
growth factors. Signiﬁcantly, Fbxo9 is overexpressed in multiple
myeloma and drives constitutive activation of the PI3K/mTORC2/Akt
pathway to promote survival [38]. In multiple myelomas with elevated
Fbxo9 expression, inhibition of Fbxo9 represents an attractive approach
to inhibit Akt signaling, one of the most important mediators of cell
survival in this disease [159]. Inhibition of CK2, the kinase that promotes
Fbxo9-mediated ubiquitylation of Tel/Tti1, may also be an interesting
therapeutic approach in multiple myeloma, particularly since CK2
inhibitors are readily available [161].Although Fbxw7 behaves as a tumor suppressor due to its
ubiquitylation activity against mitogenic substrates (e.g., Notch, c-Myc,
cyclin E), Fbxw7 functions as a pro-survival gene in multiple myeloma
by constitutively targeting the NFκB inhibitor p100 in a GSK3-
dependent manner [162]. While a number of cancers, including T-ALL,
breast cancers, and gastric adenocarcinoma often carry mutations in
the Fbxw7 gene, leading to an accumulation of mitogenic substrates
[163–165], these mutations do not occur in B-cell malignancies like
multiplemyeloma [166]. Fbxw7 and GSK3may thus serve as promising
targets for the treatment ofmultiplemyelomaswith constitutive activa-
tion of the NFκB pathway.
In a short term setting, acute delivery of an Fbxw7 inhibitor could
also be effective in tumors where this F-box protein plays a tumor sup-
pressive role by inducing cancer stem cells to proliferate and, therefore,
become susceptible to traditional chemotherapies. However, this hy-
pothesis remains to be proved experimentally.
6.1.4. Other F-box proteins
Fbxo11 mutations are present in human cancers, such as diffuse
large B cell lymphomas (DLBCLs), colon, lung, ovary, and head and
neck tumors [167–171] (and Staudt L., personal communication).
At least in DLCBLs, these mutations inhibit SCFFbxo11. The presence of
inactivating mutations suggests that Fbxo11 may function as a tumor
suppressor, whose loss of function contributes to the pathogenesis of
DLBCL (via BCL6 accumulation) and other cancers (through the stabili-
zation of unidentiﬁed oncogenic substrates). Furthermore, inactivating
mutations have been reported for Fbxo4 in esophageal carcinoma, and
these mutations are associated with an increase in cyclin D1 levels.
The mutations occur in the N-terminal regulatory regions of Fbxo4
and disrupt dimerization and activation [172]. Moreover, there is evi-
dence for the loss ofα/B crystallin in breast cancer and a corresponding
increase in cyclin D1 levels.α/B crystallin is the substrate adaptor for cy-
clin D1 together with Fbxo4 [63,173]. These data suggest a tumor sup-
pressor role for the SCFFbxo4-α/B crystallin ligase in human tumors based
on its ability to destabilize cyclin D1. Finally, cyclin F has been reported
to be downregulated in hepatocelular carcinoma (HCC). In this context,
low cyclin F expressionwas an independent poor prognostic marker for
overall survival and correlated with tumor size and clinical stage [174].
Given the role of cyclin F in regulating centrosome homeostasis and the
balanced abundance of dNTPs, these ﬁndings hint at a function for
cyclin F as a tumor suppressor in HCC by maintaining genomic stabilty
[75,76].
6.2. Strategies to target CRLs
In theory, targets for inhibiting substrate degradation by the
ubiquitin proteasome system can involve any of the three enzymes
involved in ubiquitin transfer, including the E1 activating, the E2 con-
jugating, and the E3 ligase enzymes. These approaches would be
expected to inhibit most or certain ubiquitin ligase families, when
targeting E1 or E2 enzymes, respectively, and become highly speciﬁc
when targeting single E3 ligases.
6.2.1. Targeting E1 ubiquitin activating enzymes
E1s (of which there are two in mammals) catalyze the initial step
in ubiquitin conjugation, which involves an ATP-dependent covalent
attachment of ubiquitin to its active cysteine site [4]. Efforts have
been undertaken to target E1. These studies have yielded candidate
compounds like PYR-41, an irreversible ubiquitin E1 inhibitor, but
further investigations will be necessary to assess if they are clinical
candidates [175]. Additional efforts have been directed to the E1s
for ubiquitin like proteins (such as NEDD8, SUMO, etc.). Recently,
MLN4924, an adenosine sulfamate analog, was reported to inhibit
the E1 responsible for NEDDylation, the covalent addition of NEDD8
to substrates [176]. The cullin family of proteins are the most impor-
tant substrates for neddylation, and the activity of SCF and other CRLs
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for the ubiquitin E1s, a small molecule inhibitor of the NEDD8 E1
would only inhibit CRLs. Currently, MLN4924 is in phase I/II clinical
trials for the treatment of multiple myeloma and non-Hodgkins
lymphoma, and the preclinical data suggest high efﬁcacy in AML
[179,180].
6.2.2. Targeting E2 ubiquitin conjugating enzymes
Together with the E3 ligase, E2s mediate the transfer of ubiquitin to
the target protein and govern the type and extent of ubiquitin linkage
[181]. The human genome encodes at least 38 E2 enzymes, and Cdc34
(aka Ubc3) appears to be the major E2 for SCF ligases in promoting
K48-linked polyubiquitylation and proteasomal degradation [12].
Recently, CC0651, a small molecule allosteric inhibitor of Cdc34 was
reported [182]. CC0651 inhibits p27 ubiquitylation and degradation,
and it demonstrates convincing speciﬁcity for human Cdc34, as
evidenced by a lack of reactivity against any other E2/E3 pairs tested
[182]. While current data on other E2 inhibitors is limited, the develop-
ment of CC0651 indicates the feasibility of developing highly selective
inhibitors of E2s and encourages efforts to target other E2s in a similar
manner.
6.2.3. Targeting E3 ubiquitin ligases
E3 ligases determine which target protein becomes ubiquitylated.
Inhibition of a single E3 ligase would be the most selective targeting
approach, since it would affect a limited number of proteins, poten-
tially translating into a better therapeutic ratio and fewer side effects.
Most E3 ligases do not feature a canonical active site, and instead, the
active site is a protein-protein interaction with a substrate. Inhibition
of these protein–protein interactions is typically considered more dif-
ﬁcult than inhibition of a catalytic site. However, this task appears in-
creasingly feasible with advances in the structural understanding of
these interactions [183]. MDM2 is an extensively studied ubiquitin
E3 ligase with strong clinical relevance by virtue of its ability to regu-
late the abundance of the tumor suppressor p53. Previously, the
Nutlin class of imidazoline chemotypes was identiﬁed, and they spe-
ciﬁcally disrupt the protein-protein binding interface between MDM2
and p53, stabilizing p53 [184]. Nutlin-3a is the most promising candi-
date and has favorable preclinical characteristics in terms of pharma-
cological properties and toxicity [185,186]. Currently, Nutlin-3a is
being investigated in early phase clinical trials for several solid and
hematological tumor entities, setting a precedent for the speciﬁc inhi-
bition of a ligase-substrate pair as a promising clinical approach.
In the case of SCF complexes, inhibition of either the F-box protein–
substrate interface or the recruitment of the F-box protein to the
SCF core are attractive strategies to selectively inhibit individual
ubiquitylation events. In this regard, the small molecule inhibitor
CpdA has previously been found to prevent the binding of Skp2 to the
SCF ligase complex, inducing G1/S arrest and apoptosis by stabilizing
p27, p21, and other Skp2 target proteins. In addition, CpdA sensitized
multiple myeloma cells to cytostatic agents and bortezomib, and it
was active against both myeloid and lymphoblastoid leukemia blasts
[187].
Independent studies have recently demonstrated the feasibility of
direct inhibition of the interfaces between the F-box protein and
either the substrate or SCF core. SCF-I2 is an allosteric inhibitor of
substrate recognition by the yeast F-box protein Cdc4 and inhibits
binding and ubiquitylation of substrates. SCF-I2 inserts itself between
the β-strands of the WD-40 propeller domain of Cdc4, impairing
recognition of Cdc4-speciﬁc phosphodegrons [188]. In addition, a
recent study screened for inhibitors that selectively target the
p27-binding interface formed by Skp2-Cks1. This approach yielded
four compounds that stabilize the expression of p27 in different
human cancer cell lines and induce cell cycle arrest in G1 [189]. Finally,
a chemical genetics screen for enhancers of rapamycin identiﬁed
SMER3, an inhibitor of the SCFMet30 ligase. SMER3 speciﬁcally inhibitsbinding of the F-box protein subunit Met30 to the SCF core, stabilizing
substrates such as Met4 [190].
Another approach to prevent substrate degradation at the E3 ligase
level is to inhibit the kinase that phosphorylates a substrate to mark it
for degradation. This approach particularly applies to SCF ubiquitin li-
gases, as it is well established that substrate phosphorylation is fre-
quently a prerequisite for F-box protein binding [13,151,191]. Indeed,
kinases like Plk1, which control the degradation of tumor suppressors,
are potential targets, and inhibitors have already entered early clinical
trials [192]. Notably, this approach could quickly impact the clinic, as in-
hibitors to numerous kinases are readily available, but broader applica-
tion will require further investigations.
Together, SCF ligases are promising therapeutic target structures,
whose pharmacological modulation would offer highly speciﬁc thera-
peutic approaches to a wide variety of malignancies. The success of
this undertaking will largely depend on the pharmacological progress
in developing speciﬁc inhibitors of F-box proteins and a better mech-
anistic understanding of the many uncharacterized F-box proteins,
both with regard to their substrates and the posttranslational modiﬁ-
cations that prime them for SCF-dependent ubiquitylation. Finally, it
will be critical to further deﬁne tumor entities in which distinct SCF
ligases are deregulated. This data will help deﬁne distinct F-box pro-
teins as biomarkers and allow the selection of patient subpopulations
that would proﬁt from a targeted approach against SCF ligases.Acknowledgements
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